News | February 05, 2009

FDG-PET/CT Identifies Inflammatory Breast Cancer in Initial Stages

February 5, 2009 – In the largest study to date to evaluate FDG-PET/CT (Fluorodeoxyglucose positron emission tomography combined with computed tomography) in the initial staging of inflammatory breast cancer (IBC), researchers at M. D. Anderson Cancer Center, Houston, TX, identified the precise location and extent of metastasis, offering the potential for a better prognosis for patients with this rare, but aggressive form of breast cancer.

In the study, published in the February issue of The Journal of Nuclear Medicine, researchers reported findings in 41 women between the ages of 25 and 71 with unilateral primary IBC who had originally presented with swelling, some pain and skin changes, such as rash and skin discoloration. A palpable mass was not evident on physical examination in 26 patients (63 percent), which is not unusual in this form of breast cancer, and 90 percent had no symptoms of distant metastasis (disease spread beyond the breast).

Each patient underwent a whole-body FDG-PET/CT exam. The scans showed that nearly half of the patients (49 percent) had distant metastasis, and 27 percent had disease in multiple sites. Neither finding had been previously detected by conventional imaging. These results were confirmed by biopsy and supplementary imaging.

"PET/CT is useful in staging IBC because it provides information on both the primary disease site as well as disease involvement throughout the rest of the body," said Homer A. Macapinlac, M.D., chair and professor of nuclear medicine at the University of Texas, M. D. Anderson Cancer Center, Houston, TX. "In addition to detecting the presence of cancer, PET/CT is able to demonstrate the biology of cancer - revealing how aggressive the disease is - which can help physicians develop appropriate therapy approaches."

"Breast cancer is a systemic disease, not just a local one. Most imaging modalities are localized and will therefore miss the spread of disease that is frequently present by the time IBC is diagnosed," Macapinlac said. "The use of a whole-body modality such as PET/CT with its higher sensitivity, however, allows us to pinpoint metastasis in other parts of the body; for example, behind the clavicle - which can not be detected in a physical exam - or in the abdominal organs or pelvic lymph nodes."

IBC tends to grow more quickly and aggressively than the more common types of breast cancer. Upon diagnosis, it is already considered to be at least stage IIIB (locally advanced) and even stage IV if it has spread to distant parts of the body. Because of this, IBC has been harder to successfully treat than other types of breast cancer. Knowing the extent of the disease at the start could have a great impact on the outcome for many patients, Macapinlac added.

"With FDG-PET/CT, physicians are able to accurately determine the location of metastases early in the disease process when appropriate treatment can be administered. Furthermore, a PET/CT procedure for IBC patients may be less than or equivalent to the total cost of separately imaging multiple organs and would require a single hospital visit and decreased imaging time when compared to the time required for a battery of regional staging studies," Macapinlac said.

The researchers would like to see future studies that use PET/CT earlier in the process and also to track therapy response to determine whether or not it is succeeding.

"Knowing the extent of disease up front has great implication for prognosis," Macapinlac said. "IBC is a treatable disease. The sooner we can determine the extent, the sooner we can begin aggressive therapy."

PET provides information about how the body is functioning at the cellular level, while CT provides an anatomical rendering of the inside of the body. In an FDG-PET/CT scan, the CT first produces detailed images of the inner anatomy of the body. The patient is then injected with a small amount of a radioactive drug, which is F-18-labeled glucose, and PET is performed. Because fast-growing cancer cells feed on sugars such as glucose, PET/CT delineates areas where the glucose accumulates in the body, identifying the location of cancer cells.

According to the American Cancer Society, IBC accounts for approximately 1 to 3 percent of all breast cancers diagnosed in the United States. It tends to occur in younger women, and African-Americans appear to be at higher risk. Physicians call the disease "inflammatory breast cancer" because the affected breast displays the same symptoms that occur with inflammation. However, the symptoms of IBC are not caused by infection or injury, but by cancer cells blocking lymph vessels in the skin. Patients often do not have a breast lump, and symptoms may not show up on a mammogram. Because it doesn't look like a typical breast cancer, the disease can be harder to diagnose.

Related Content

Representative maximum-intensity projection PET images of a healthy human volunteer injected with 64Cu-NOTA-EB-RGD at 1, 8, and 24 hours after injection. Axial MRI and PET slices of glioblastoma patient injected with 64Cu-NOTA-EB-RGD at different time points after injection. Image courtesy of Jingjing Zhang et al., Peking Union Medical College Hospital, Beijing, China/ Xiaoyuan Chen et al., Laboratory of Molecular Imaging and Nanomedicine, NIBIB/NIH, Bethesda, USA

Representative maximum-intensity projection PET images of a healthy human volunteer injected with 64Cu-NOTA-EB-RGD at 1, 8, and 24 hours after injection. Axial MRI and PET slices of glioblastoma patient injected with 64Cu-NOTA-EB-RGD at different time points after injection. Image courtesy of Jingjing Zhang et al., Peking Union Medical College Hospital, Beijing, China/ Xiaoyuan Chen et al., Laboratory of Molecular Imaging and Nanomedicine, NIBIB/NIH, Bethesda, USA

News | PET Imaging | July 15, 2020
July 15, 2020 — A first-in-human study presented at the Society of...
PET/CT imaging showing uptake and retention of 86Y-NM600 (imaging agent) in immunocompetent mice bearing prostate tumors. PET imaging data was employed to estimate tumor dosimetry and prescribe an immunomodulatory 90Y-NM600 (therapy agent) injected activity. Image courtesy of R Hernandez et al., University of Wisconsin-Madison, WI.

PET/CT imaging showing uptake and retention of 86Y-NM600 (imaging agent) in immunocompetent mice bearing prostate tumors. PET imaging data was employed to estimate tumor dosimetry and prescribe an immunomodulatory 90Y-NM600 (therapy agent) injected activity. Image courtesy of R Hernandez et al., University of Wisconsin-Madison, WI.

News | PET-CT | July 15, 2020
July 15, 2020 — ...
Adult male with decades of right neck pain, discomfort and tightening following birth injury. The patient had failed multiple standard therapeutic maneuvers before presenting for 18F-FDG PET/MR imaging. Images shows abnormally elevated FDG uptake (white arrows; SUVmax = 1.2) observed in a linear pattern in the space in the posterolateral right neck, between the oblique capitis inferior and the semispinalis capitis muscles, where the greater occipital nerve resides. By comparison, the same region on the cont

Adult male with decades of right neck pain, discomfort and tightening following birth injury. The patient had failed multiple standard therapeutic maneuvers before presenting for 18F-FDG PET/MR imaging. Images shows abnormally elevated FDG uptake (white arrows; SUVmax = 1.2) observed in a linear pattern in the space in the posterolateral right neck, between the oblique capitis inferior and the semispinalis capitis muscles, where the greater occipital nerve resides. By comparison, the same region on the contralateral, asymptomatic side of the neck has an SUVmax = 0.7. This result encouraged a surgeon to explore the area. The surgeon ultimately found a collection of small arteries wrapped around the nerve in this location. The small arteries underwent lysis by the surgeon and the patient reported tremendous relief of symptoms. (A) Coronal thick slab MIP of 18F-FDG PET. (B) Axial LAVA FLEX MRI through the cervical spine. (C) Axial PET at the same slice as the axial MRI. (D) Fused axial PET/MRI. Image courtesy of Cipriano, et al., Stanford University, CA.

News | SNMMI | July 14, 2020
July 14, 2020 — A new molecular imaging approach utilizing 18F-FDG...
Left: Total-body PET/CT in psoriatic arthritis: multiple joints affected, shoulders, elbows, wrists, knees, ankles and small joints of the hands/feet. Arrow: left wrist; arrowhead: right wrist. Middle: Total-body PET/CT in rheumatoid arthritis: multiple joints affected, right shoulder, small joints of the left hand. Arrowhead at the 4th proximal interphalangeal joint shows classic ring-like uptake pattern. Arrow on the foot images demonstrates the hammer toe deformity besides big toe arthritis. Right: Total

Left: Total-body PET/CT in psoriatic arthritis: multiple joints affected, shoulders, elbows, wrists, knees, ankles and small joints of the hands/feet. Arrow: left wrist; arrowhead: right wrist. Middle: Total-body PET/CT in rheumatoid arthritis: multiple joints affected, right shoulder, small joints of the left hand. Arrowhead at the 4th proximal interphalangeal joint shows classic ring-like uptake pattern. Arrow on the foot images demonstrates the hammer toe deformity besides big toe arthritis. Right: Total-body PET/CT in osteoarthritis: affected joints include the left elbow, right knee (arrow) and right big toe (arrowhead). Image courtesy of YG Abdelhafez et al., University of California Davis, Sacramento, CA.

News | SNMMI | July 14, 2020
July 14, 2020 — For the first time, physicians can examine the systemic burden of inflammatory arthritis simultaneous
World's largest radiation oncology meeting will offer full conference on interactive platform October 25-28, 2020
News | ASTRO | July 09, 2020
July 9, 2020 — Registration opens today for the American Society for Radiation Oncology's (...
Nuclear Cardiology Optimistic About Return to Pre-COVID-19 Exam Levels. An American Society of Nuclear Cardiology (ASNC) member survey are confident nuclear cardiology volumes will return to pre-pandemic levels. #COVID19 #SARScov2
News | Nuclear Imaging | June 01, 2020
June 1, 2020 — While acknowledging the challenges their specialty is facing, more than two-thirds of respondents to a
MERCK and RefleXion Medical announced a collaboration to evaluate KETRUDA (immunotherapy) with biology-guided radiotherapy - BgRT -  a new radiation machine developed to treat all stages of cancer.

MERCK and RefleXion Medical announced a collaboration to evaluate KETRUDA (immunotherapy) with biology-guided radiotherapy - BgRT -  a new radiation machine developed to treat all stages of cancer.

 

News | Radiation Therapy | June 01, 2020
June 1, 2020 — RefleXion Medical, a therape
The Society of Nuclear Medicine and Molecular Imaging's 2020 annual meeting has been reimagined, and is now the SNMMI 2020 Annual Meeting — Virtual Edition
News | Coronavirus (COVID-19) | April 30, 2020
April 30, 2020 — The Society of Nuclear Medicine and Molecular Imaging's 2020 annual meeting has been reimagined, and
 Siemens Healthineers has received clearance from the Food and Drug Administration (FDA) for its AIDAN artificial intelligence technologies on the Biograph family of positron emission tomography/computed tomography (PET/CT) systems

 Siemens Healthineers received clearance from the FDA for its AIDAN artificial intelligence technologies on the Biograph family of positron emission tomography/computed tomography (PET/CT) systems.

News | Artificial Intelligence | April 22, 2020
April 22, 2020 — Siemens Healthineers has received